PharmaEssentia - Public Comps and Valuation Multiples

PharmaEssentia Overview

About PharmaEssentia

PharmaEssentia Corp is engaged in medicine discovery, supplements in developing specialty pharmaceutical reagents, API, and new drug pattern developments. It focuses on Hematology, Oncology, and Infectious Diseases. The company derives its revenue from the sales of medicine products. Geographically, the company generates maximum revenue from America, followed by Europe, Asia (excluding Taiwan), and Taiwan.

Founded

2000

HQ

Employees

350

Website

pharmaessentia.com

Sectors

Biopharmaceuticals
Drug Development & Therapeutics
BioTech

Financials

LTM Revenue $454M

LTM EBITDA $136M

EV

$5.5B

Valuation Multiples

Multiples.vc

Valuation Multiples for 15K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

Browse Valuation Multiples

PharmaEssentia Financials

As of August 2025, PharmaEssentia reported last 12-month revenue of $454M and EBITDA of $136M.

In the same period, PharmaEssentia generated $402M in LTM gross profit and $150M in net income.

See PharmaEssentia valuation multiples based on analyst estimates

PharmaEssentia P&L

In the most recent fiscal year, PharmaEssentia reported revenue of $318M and EBITDA of $111M.

PharmaEssentia expects next 12-month revenue of XXX and NTM EBITDA of XXX

See PharmaEssentia valuation multiples based on analyst estimates

	LTM	NTM	Last FY	FY 2025	FY 2026	FY 2027
Revenue	$454M	XXX	$318M	XXX	XXX	XXX
Gross Profit	$402M	XXX	$280M	XXX	XXX	XXX
Gross Margin	89%	XXX	88%	XXX	XXX	XXX
EBITDA	$136M	XXX	$111M	XXX	XXX	XXX
EBITDA Margin	30%	XXX	35%	XXX	XXX	XXX
EBIT	$127M	XXX	$56.8M	XXX	XXX	XXX
EBIT Margin	28%	XXX	18%	XXX	XXX	XXX
Net Profit	$150M	XXX	$96.9M	XXX	XXX	XXX
Net Margin	33%	XXX	30%	XXX	XXX	XXX
Net Debt	XXX	XXX	n/a	XXX	XXX	XXX

Financial data powered by Morningstar, Inc.

.seo-only-financials-wrapper { position: static; left: auto; width: auto; height: auto; overflow: visible; }

Financial performance metrics for PharmaEssentia including revenue, profitability, and margin analysis across different time periods. The company reported last twelve months revenue of $454M. EBITDA for the last twelve months was $136M. In the most recent fiscal year, PharmaEssentia achieved $318M in revenue and $111M in EBITDA.
Financial Metric	Last Twelve Months (LTM)	Next Twelve Months (NTM)	Most Recent Fiscal Year	Current Fiscal Year (2025)	Next Fiscal Year (2026)	Two Years Forward (2027)
Total Revenue	$454M	Analyst estimates available to subscribers	$318M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Gross Profit	$402M	Analyst estimates available to subscribers	$280M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Gross Profit Margin	88.5% gross margin	Analyst estimates available to subscribers	87.9% gross profit margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBITDA (Earnings Before Interest, Taxes, Depreciation, Amortization)	$136M	Analyst estimates available to subscribers	$111M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBITDA Margin	29.8% EBITDA margin	Analyst estimates available to subscribers	34.8% EBITDA margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBIT (Earnings Before Interest and Taxes)	$127M	Analyst estimates available to subscribers	$56.8M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBIT Margin	28.0% EBIT margin	Analyst estimates available to subscribers	17.8% EBIT margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Income (Net Profit)	$150M	Analyst estimates available to subscribers	$96.9M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Profit Margin	33.1% net profit margin	Analyst estimates available to subscribers	30.5% net profit margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Debt Position	Detailed debt information available to subscribers	Detailed debt information available to subscribers	n/a	Detailed debt information available to subscribers	Detailed debt information available to subscribers	Detailed debt information available to subscribers

Financial Performance Summary for PharmaEssentia

This financial data table provides comprehensive performance metrics for PharmaEssentia, a company based in Taiwan. The metrics include revenue, profitability measures, and operational efficiency indicators across multiple time periods.

Recent Performance Highlights

PharmaEssentia generated $454M in revenue over the last twelve months.
The company achieved $136M in EBITDA over the last twelve months.
Gross profit for the last twelve months was $402M.
Net income over the last twelve months reached $150M.

Fiscal Year Performance

In the most recent fiscal year, PharmaEssentia reported $318M in total revenue.
Fiscal year EBITDA was $111M.
The company maintained a gross profit margin of 87.9% in the most recent fiscal year.
EBITDA margin for the fiscal year was 34.8%.
Net profit margin reached 30.5% in the most recent fiscal year.

This financial data is sourced from Morningstar, Inc. and represents the most recent available information for PharmaEssentia. Forward-looking estimates and detailed financial projections are available through our premium subscription service.

PharmaEssentia Stock Performance

PharmaEssentia has current market cap of TWD 189B (or $6.2B), and EV of TWD 169B (or $5.5B).

Market Cap Evolution

PharmaEssentia Stock Data

As of September 30, 2025, PharmaEssentia's stock price is TWD 512 (or $17).

See PharmaEssentia trading valuation data

EV	Market Cap	Price 1D	Price 1M	Price 3M	Price 12M	EPS
$5.5B	$6.2B	XXX	XXX	XXX	XXX	$0.40

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Start Free Trial

PharmaEssentia Valuation Multiples

PharmaEssentia's trades at 17.4x EV/Revenue multiple, and 50.1x EV/EBITDA.

See valuation multiples for PharmaEssentia and 15K+ public comps

PharmaEssentia Financial Valuation Multiples

As of September 30, 2025, PharmaEssentia has market cap of $6.2B and EV of $5.5B.

Equity research analysts estimate PharmaEssentia's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

PharmaEssentia has a P/E ratio of 41.2x.

	LTM	NTM	Last FY	FY 2025	FY 2026	FY 2027
Market cap (current)	$6.2B	XXX	$6.2B	XXX	XXX	XXX
EV (current)	$5.5B	XXX	$5.5B	XXX	XXX	XXX
EV/Revenue	12.2x	XXX	17.4x	XXX	XXX	XXX
EV/EBITDA	40.9x	XXX	50.1x	XXX	XXX	XXX
EV/EBIT	43.6x	XXX	97.6x	XXX	XXX	XXX
EV/Gross Profit	13.8x	XXX	n/a	XXX	XXX	XXX
P/E	41.2x	XXX	63.9x	XXX	XXX	XXX
EV/FCF	30.0x	XXX	103.1x	XXX	XXX	XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get PharmaEssentia Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Start Free Trial

PharmaEssentia Margins & Growth Rates

PharmaEssentia's last 12 month revenue growth is 47%

PharmaEssentia's revenue per employee in the last FY averaged $0.9M, while opex per employee averaged $0.6M for the same period.

PharmaEssentia's rule of 40 is 34% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

PharmaEssentia's rule of X is 148% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

See operational valuation multiples for PharmaEssentia and other 15K+ public comps

PharmaEssentia Operational Valuation Multiples

	LTM	NTM	Last FY	FY 2025	FY 2026	FY 2027
Revenue Growth	47%	XXX	51%	XXX	XXX	XXX
EBITDA Margin	30%	XXX	35%	XXX	XXX	XXX
EBITDA Growth	88%	XXX	n/a	XXX	XXX	XXX
Rule of 40	34%	XXX	82%	XXX	XXX	XXX
Bessemer Rule of X	XXX	XXX	148%	XXX	XXX	XXX
Revenue per Employee	XXX	XXX	$0.9M	XXX	XXX	XXX
Opex per Employee	XXX	XXX	$0.6M	XXX	XXX	XXX
S&M Expenses to Revenue	XXX	XXX	25%	XXX	XXX	XXX
G&A Expenses to Revenue	XXX	XXX	n/a	XXX	XXX	XXX
R&D Expenses to Revenue	XXX	XXX	27%	XXX	XXX	XXX
Opex to Revenue	XXX	XXX	70%	XXX	XXX	XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics

Pharma Analytics

Private Equity

ERP Software

Developer Tools

Consumer SaaS

Streaming Platforms

Explore Valuation Multiples by Industry

Start Free Trial